Arbutus Biopharma Corporation

ABUS · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analyst

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders20.4%

Institutions72.3%

Public / Other

	You	Peer avg
P/E	6.5	7.1
Revenue Growth	-90.6%	-35.9%
ROE	89.6%	-29.1%

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$14.08M	$6.17M	$18.14M	$39.02M	$10.99M	$6.91M	$6.01M	$5.95M	$10.70M	$1.49M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$38.16M	-$76.32M	-$78.10M	-$65.46M	-$73.52M	-$57.81M	-$144.07M	-$89.78M	-$110.93M	-$491.64M
Operating income as a percentage of revenue.	-271.0%	-1236.7%	-430.5%	-167.8%	-669.1%	-836.1%	-2396.8%	-1510.2%	-1036.7%	-32973.8%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$33.50M	-$69.92M	-$72.85M	-$69.46M	-$76.25M	-$63.74M	-$153.72M	-$57.06M	-$84.41M	-$384.16M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$0.00	$0.00	$-0.83	$-1.00	$-2.00	$-1.00	$-1.00	$-7.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	$0.00	$0.00	$-0.83	–	–	$-1.00	$-1.00	$-7.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$18.01M	$36.33M	$26.29M	$30.78M	$109.28M	$52.25M	$31.80M	$36.94M	$54.29M	$23.41M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$94.62M	$131.71M	$144.40M	$195.42M	$204.49M	$137.08M	$105.53M	$227.91M	$237.16M	$275.92M
Everything the company owes — debt, unpaid bills, and other obligations.	$18.04M	$34.34M	$38.38M	$58.57M	$35.05M	$35.11M	$32.79M	$27.67M	$54.69M	$72.91M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$76.58M	$97.37M	$106.02M	$136.85M	$169.44M	$101.97M	$72.74M	$200.23M	$182.47M	$203.00M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$39.64M	-$64.85M	-$85.94M	-$35.36M	-$67.53M	-$51.44M	-$71.01M	-$67.87M	-$48.64M	-$57.88M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$0	$182000	$1.01M	$512000	$809000	$229000	$589000	$1.14M	$7.26M	$4.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$39.64M	-$65.03M	-$86.94M	-$35.87M	-$68.34M	-$51.67M	-$71.59M	-$69.00M	-$55.90M	-$61.88M

Arbutus Biopharma Corporation

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison

Income Statement

Balance Sheet

Cash Flow Statement